We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Screening Test Detects Tropical Disease in Blood Donors

By LabMedica International staff writers
Posted on 10 May 2010
Print article
Image: Light micrograph of a section through clusters (small clumps of purple bodies) of Trypanosoma cruzi protozoans in the heart muscle of a patient suffering from Chagas disease (Photo courtesy of Sinclair Stammers / SPL).
Image: Light micrograph of a section through clusters (small clumps of purple bodies) of Trypanosoma cruzi protozoans in the heart muscle of a patient suffering from Chagas disease (Photo courtesy of Sinclair Stammers / SPL).
A screening test that detects antibodies to a lethal tropical parasite will help safeguard blood for transfusions and tissue and organ recipients.

The test is fully automated, and is highly sensitive and specific for the blood-borne parasite, Trypanosoma cruzi, the causative agent of Chagas diseases. It uses serum or plasma from donors of whole blood or blood components as well as from organ or tissue donors and detects antibodies to T. cruzi. The assay can be used to screen blood from the transplant donor whether the heart is still beating or even if it is not. It is not designed to be used with cord blood.

Manufactured by Abbott Laboratories (Abbot Park, IL, USA), the Abbott Prism Chagas test is a two-step sandwich chemiluminescent assay that uses recombinant parasite antigens coated on microparticles. The test kit also contains anti-human conjugate and alkaline hydrogen peroxide for generating the photons. The test has detected antibodies to the parasite in over 1,000 donors since testing was instituted in 2007.

Reports indicate that 1 in every 27,500 blood donors in the United States will test positive for Chagas Disease. Blood donations in the United States exceed 15 million a year. The test is highly specific and does not react with serum of patients infected with other tropical or sexually transmitted diseases. An estimated 8-11 million people are known to be suffering from Chagas Disease in Mexico, Central and South America. The disease progresses from an acute phase to a chronic one, and is often undetected. The parasite has a predilection for the internal organs, especially the heart.

Karen Midthun, M.D., acting director of the US Food and Drug Administration's Center for Biologics Evaluation and Research, (FDA; Silver Spring, MD, USA), said that "Screening for T. cruzi is an important safety measure to help protect our blood supply and help prevent the spread of Chagas disease." This second-generation test has received FDA approval.

Related Links:
Abbott Laboratories
US Food and Drug Administration


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.